“This systematic evaluation compared the efficacy and safety profiles of gemcitabine combined with targeted agents (GEM + TA) versus gemcitabine administered as monotherapy or combined with placebo (GEM ± PLC) in locally advanced/metastatic pancreatic cancer (LA/MPC) patients. Based on the results from this analysis, the addition of targeted agents to a regimen of gemcitabine treatment does not bring survival benefits except 1–year survival rate to patients with LA/MPC.”
The gist: Researchers analyzed data from ten different clinical trials that tested whether the chemotherapy drug gemcitabine worked better for pancreatic cancer patients when combined with targeted therapy drugs. (Targeted therapies are drugs developed to fight tumors that have specific genetic mutations, as detected by molecular testing.) Not many benefits were found for the combination treatments, except that patients who took gemcitabine combined with targeted therapy were more likely be alive one year later than patients who only took gemcitabine.